SCHEMBL2297219

SCHEMBL2297219

O=[N+]([O-])C1CCCCN1c1ccccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 5/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GRM1 Q13255 1/20 0.38
MITF O75030 1/20 0.38
POLB P06746 1/20 0.38
MMP1 P03956 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
GAA P10253 1/20 0.37
TERT O14746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675145 0.77 L3MBTL1 (0.38) ALDH1A1SMN1; SMN2HSD17B10MAPTL3MBTL1
SCHEMBL28120472 0.74 NPC1 (0.34) ALDH1A1MAPTHTTNPC1TERT
SCHEMBL5482822 0.74 KDM4E (0.42) ALDH1A1KDM4EHSD17B10MAPTCYP1A2
SCHEMBL27268114 0.74 LMNA (0.50) ALDH1A1SMN1; SMN2KDM4EMAPTCYP1A2
SCHEMBL6262600 0.73 KDM4E (0.44) ALDH1A1KDM4EHSD17B10MAPTHTT
SCHEMBL16238706 0.72 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2KDM4EHSD17B10HTT
SCHEMBL6600008 0.72 KMT2A (0.42) ALDH1A1SMN1; SMN2MAPTL3MBTL1
SCHEMBL2222270 0.71 GPR119 (0.45) ALDH1A1KDM4EHSD17B10MAPTCYP1A2
SCHEMBL28059132 0.71 MMP1 (0.47) ALDH1A1KDM4EHSD17B10MAPTHTT
SCHEMBL20336407 0.71 ALDH1A1 (0.42) ALDH1A1KDM4EHSD17B10MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030270-B2 Methods for identifying GLP-1 secretagogues ARENA PHARMACEUTICALS, INC. (US) 2011-10-04 US disclosed
US-8022034-B2 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level ARENA PHARMACEUTICALS, INC. (US) 2011-09-20 US disclosed
US-8003597-B2 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level ARENA PHARMACEUTICALS, INC. (US) 2011-08-23 US disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed